CA3083354A1 - Interaction of fibroblasts and immune cells for activation and uses thereof - Google Patents

Interaction of fibroblasts and immune cells for activation and uses thereof Download PDF

Info

Publication number
CA3083354A1
CA3083354A1 CA3083354A CA3083354A CA3083354A1 CA 3083354 A1 CA3083354 A1 CA 3083354A1 CA 3083354 A CA3083354 A CA 3083354A CA 3083354 A CA3083354 A CA 3083354A CA 3083354 A1 CA3083354 A1 CA 3083354A1
Authority
CA
Canada
Prior art keywords
days
hours
cells
fibroblasts
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3083354A
Other languages
English (en)
French (fr)
Inventor
Pete O'HEERON
Thomas Ichim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Figene LLC
Original Assignee
Figene LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Figene LLC filed Critical Figene LLC
Publication of CA3083354A1 publication Critical patent/CA3083354A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3083354A 2017-11-29 2018-11-29 Interaction of fibroblasts and immune cells for activation and uses thereof Pending CA3083354A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762591858P 2017-11-29 2017-11-29
US62/591,858 2017-11-29
PCT/US2018/063001 WO2019108756A1 (en) 2017-11-29 2018-11-29 Interaction of fibroblasts and immune cells for activation and uses thereof

Publications (1)

Publication Number Publication Date
CA3083354A1 true CA3083354A1 (en) 2019-06-06

Family

ID=66665803

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3083354A Pending CA3083354A1 (en) 2017-11-29 2018-11-29 Interaction of fibroblasts and immune cells for activation and uses thereof

Country Status (7)

Country Link
US (2) US12233094B2 (enExample)
EP (1) EP3716988A4 (enExample)
JP (2) JP7387603B2 (enExample)
CN (1) CN111601606A (enExample)
AU (1) AU2018375151B2 (enExample)
CA (1) CA3083354A1 (enExample)
WO (1) WO2019108756A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070454A (zh) * 2023-10-18 2023-11-17 北京细胞治疗集团有限公司 一种car-t细胞的制备方法

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132594A1 (en) * 2017-01-11 2018-07-19 Spinalcyte, Llc Methods of enhancing fibroblast therapeutic activity
AU2018254498B2 (en) 2017-04-19 2023-08-03 Figene, Llc Stimulation of angiogenesis by fibroblast derived exosomes
US11959102B2 (en) * 2017-12-20 2024-04-16 Figene, Llc Augmentation of fibroblast regenerative activity
EP3843758A4 (en) * 2018-08-27 2022-06-08 Figene, LLC CHIMERIC ANTIGEN RECEPTOR FIBROBLAST CELLS FOR THE TREATMENT OF CANCER
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2022506683A (ja) 2018-11-04 2022-01-17 フィジーン、エルエルシー 膵臓移植のファシリテーターとして繊維芽細胞を用いる１型糖尿病の治療方法および組成物
EP3873503B1 (en) 2018-11-04 2024-07-24 Figene, LLC Treatment of cachexia using fibroblast cells and products thereof
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用
WO2020150567A1 (en) * 2019-01-17 2020-07-23 Figene, Llc Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
WO2020243504A1 (en) * 2019-05-31 2020-12-03 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
EP3982984A4 (en) * 2019-06-12 2023-07-12 Figene, LLC INCREASE OF THERAPEUTIC ACTIVITY OF FIBROBLAST BY RNA
AU2020302908A1 (en) * 2019-06-28 2022-02-24 Figene, Llc Administration of fibroblasts and derivatives thereof for treatment of type 2 diabetes
US12648968B2 (en) 2019-09-09 2026-06-09 Spinalcyte Llc Fibroblast and fibroblast-immunocyte combinations for treatment of subconcussive- and concussive-associated neurological damage
WO2021076674A1 (en) * 2019-10-15 2021-04-22 Figene, Llc Fibroblast-based immunotherapy of graves disease
EP4051689A4 (en) * 2019-11-01 2023-11-29 Figene, LLC FIBROBLAST THERAPY TO TREAT SCLEROSING CHOLANGITIS
CN115297873A (zh) * 2019-11-08 2022-11-04 梅约医学教育与研究基金会 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
WO2021097434A1 (en) * 2019-11-15 2021-05-20 Figene, Llc Fibroblast therapy for inflammatory bowel disease
US12576112B2 (en) 2019-12-26 2026-03-17 Spinalcyte Llc Inhibition of TNF-alpha by fibroblasts and fibroblast exosomes
AU2020412623A1 (en) 2019-12-26 2022-07-14 Figene, Llc Prevention and treatment of kidney failure by administration of fibroblasts and products thereof
US20230026352A1 (en) 2019-12-26 2023-01-26 Figene, Llc Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
RU2727751C1 (ru) * 2020-01-09 2020-07-23 Сергей Николаевич Лепетунов Способ продления безрецидивного периода интерстициального цистита
EP4117688A4 (en) * 2020-03-13 2024-06-12 Figene, LLC GENERATING AUTOIMMUNE-INHIBITING T CELLS THROUGH FIBROBLAST-MEDIATED FORMATION
WO2021202031A1 (en) * 2020-03-30 2021-10-07 Figene, Llc Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
EP4142751A4 (en) * 2020-04-01 2025-01-08 Figene, LLC Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
IL297366A (en) 2020-04-20 2022-12-01 Duogenic Stemcells Corp Modified macrophages, preparations and uses thereof
JP2023524679A (ja) * 2020-04-30 2023-06-13 フィジーン、エルエルシー 癌線維芽細胞を標的化するための免疫療法の方法および組成物
US20230248777A1 (en) * 2020-05-29 2023-08-10 Figene, Llc Augmentation of fibroblast cell therapy efficacy by microbiome manipulation
CN111643526A (zh) * 2020-07-14 2020-09-11 贵州金元泰生物科技有限公司 一种用于延缓卵巢衰老及防治老年痴呆和抑郁的间充质干细胞制剂
WO2022016184A1 (en) * 2020-07-14 2022-01-20 Figene, Llc Augmentation of fibroblast therapeutic activity by complement blockade and/or inhibition
US20240238271A1 (en) * 2020-11-25 2024-07-18 Shanghai Juncell Therapeutics Co., Ltd. Pharmaceutical composition for enhancing cell killing, and use thereof
US20240000854A1 (en) * 2020-12-04 2024-01-04 PRIMORIS THERAPEUTICS Co., Ltd. Method for preparing high-concentration stem cell exosomes with enhanced anti-inflammatory and regenerative functions using lipopolysaccharide and lipoteichoic acid
CN112553155A (zh) * 2020-12-28 2021-03-26 山东省齐鲁干细胞工程有限公司 一种脐带血间充质干细胞培养方法
CA3206049A1 (en) * 2021-02-23 2022-09-01 John Cho Methods for expanding regulatory t cells
CN113203781B (zh) * 2021-05-13 2022-05-31 桂林电子科技大学 一种非诊断目的基于RGO-CS-Hemin@Pt NPs纳米材料和适配体检测GPC3的方法
CN113519459B (zh) * 2021-06-11 2022-03-25 中国科学院合肥物质科学研究院 一种采用调节肝细胞ros水平的磁场发生装置在调节人/鼠肝细胞氧化应激中的应用
CN113584193B (zh) * 2021-07-06 2023-07-28 中南大学湘雅医院 毛螺菌属作为评估慢性自发性荨麻疹患者抗组胺药物疗效的标志物的应用
US20250092366A1 (en) * 2021-07-20 2025-03-20 Efm Biotech Inc. Proteolytic Enzymes for Cell Culture Media
CN113736737B (zh) * 2021-09-18 2023-09-08 四川大学华西医院 一种原代胶质瘤相关成纤维细胞培养方法
WO2023075623A1 (en) * 2021-10-26 2023-05-04 Ineb (Instituto Nacional De Engenharia Biomédica) Macrophage phenoypes for use in the treatment of intravertebral discs
US20230158080A1 (en) * 2021-11-22 2023-05-25 Spinalcyte, Llc Hormonal manipulation of fibroblast therapeutic activity
KR20230099677A (ko) * 2021-12-27 2023-07-04 주식회사 진켐 신규한 메토트렉세이트 결합체와 이의 용도
CN114213540B (zh) * 2022-02-22 2022-07-01 北京大学人民医院 一组用于髓系肿瘤免疫分型的抗体组合物及其应用
WO2023224923A2 (en) * 2022-05-16 2023-11-23 The Regents Of The University Of California Engineered cells and methods of use
CN115590887B (zh) * 2022-10-17 2026-04-03 厦门大学 诱导成纤维细胞呈现免疫抑制表型的方法
CN116554348A (zh) * 2023-04-03 2023-08-08 上海交通大学医学院附属瑞金医院 Gpc3-car-t在治疗特发性肺纤维化中的应用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
WO2025015101A1 (en) * 2023-07-11 2025-01-16 Fibrobiologics, Inc. Therapeutic use of fibroblasts for the treatment of psoriasis
KR20250023295A (ko) * 2023-08-08 2025-02-18 주식회사 현대메디텍 N-아세틸시스테인(nac)을 이용한 편도 유래 중간엽 줄기세포의 배양방법
CN117147817B (zh) * 2023-08-25 2025-11-18 上海艾棵颂生物科技有限公司 多能干细胞来源小细胞外囊泡的特征性标志物组合及其应用
CN116831234A (zh) * 2023-09-01 2023-10-03 成都铁骑力士饲料有限公司 一种缓解保育猪热应激的营养功能包及其制备方法和应用
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN117683708A (zh) * 2023-10-26 2024-03-12 中国人民解放军总医院第一医学中心 用于治疗免疫相关性肾病的药物
AU2025209928A1 (en) * 2024-01-17 2026-07-30 Newsouth Innovations Pty Limited Apparatus for production of engineered cells
WO2025207662A1 (en) * 2024-03-25 2025-10-02 Fibrobiologics, Inc. Therapeutic use of fibroblasts for the treatment of systemic lupus erythematosus
CN118045104A (zh) * 2024-04-03 2024-05-17 椎元医学技术(上海)有限公司 一种成纤维细胞制剂及其在制备预防增生性脊柱炎的药物中的应用
US20250312383A1 (en) * 2024-04-05 2025-10-09 Stemcyte, Inc. Human umbilical cord blood for use in alleviating fatigue
CN118655199B (zh) * 2024-08-19 2024-12-24 四川菊乐食品股份有限公司 一种细胞印迹电化学传感器的制备方法及利用其快速定量检测乳制品中乳酸菌的方法
WO2026092339A1 (zh) * 2024-10-28 2026-05-07 苏州血霁生物科技有限公司 Mkp增殖分化方法及其应用
CN119592507A (zh) * 2024-12-03 2025-03-11 哈尔滨优莱福生物科技有限公司 一种人外周血调节性t细胞的体外扩增试剂盒及其使用方法和应用
CN119386163B (zh) * 2025-01-03 2025-03-07 北京益华生物科技有限公司 一种提高细胞疗法再生的药物组合物及其应用
CN119638837B (zh) * 2025-01-21 2025-12-30 广东拓普灵生物医药科技有限公司 一种人脐带间充质干细胞扩增培养基及培养方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
CN1234417A (zh) 1998-11-05 1999-11-10 褚炎明 一种彩色发光塑料
CA2347914A1 (en) * 1998-11-13 2000-05-25 Osiris Therapeutics, Inc. Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
CA2422586A1 (en) * 2000-09-15 2002-03-21 The Scripps Research Institute Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US7011965B2 (en) 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
AU2003216288B2 (en) * 2002-02-13 2009-09-24 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
TWI288779B (en) * 2002-03-28 2007-10-21 Blasticon Biotech Forschung Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
US20080063652A1 (en) * 2004-03-29 2008-03-13 Cytomatrix, Llc Methods for Production of Regulatory T Cells and Uses Thereof
WO2006026730A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Cultured three dimensional tissues and uses thereof
US20070059824A1 (en) * 2005-09-12 2007-03-15 Yong Zhao Human umbilical cord blood-derived pluripotent fibroblast-like-macrophages
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
FI20065514A0 (fi) * 2006-08-16 2006-08-16 Licentia Oy Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi
EP1944361A1 (en) * 2007-01-11 2008-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for expanding monocytes
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
CA2771900A1 (en) * 2009-08-22 2011-03-10 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
AU2012300221A1 (en) * 2011-08-29 2014-04-17 Safeguard Cell Technology Inc. Isolating and therapeutic use of perivascular medicinal cells
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP6367836B2 (ja) * 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
JP6437467B2 (ja) * 2013-03-14 2018-12-19 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
ES2834129T3 (es) * 2013-06-04 2021-06-16 Selecta Biosciences Inc Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
WO2016068217A1 (ja) 2014-10-29 2016-05-06 国立大学法人山口大学 末梢血単核球又は末梢血単核球より分泌される因子を伴う線維芽細胞を含む細胞シート
US20170196951A1 (en) * 2015-01-09 2017-07-13 Batu Biologics, Inc. Polyvalent anti-tumor fibroblast vaccine
CN107208055B (zh) * 2015-01-17 2021-06-15 浙江大学 引起免疫原性反应降低的被修饰细胞
KR101867942B1 (ko) * 2015-10-22 2018-06-20 가톨릭대학교 산학협력단 바이러스 항원 특이적인 t 세포의 유도 및 증식 방법
TWI612057B (zh) * 2015-10-28 2018-01-21 大江生醫股份有限公司 可促進傷口癒合、膠原蛋白增生、血管新生、活化免疫細胞並降低傷口感染之胜肽及其應用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117070454A (zh) * 2023-10-18 2023-11-17 北京细胞治疗集团有限公司 一种car-t细胞的制备方法

Also Published As

Publication number Publication date
EP3716988A4 (en) 2021-12-15
US20250144151A1 (en) 2025-05-08
JP7387603B2 (ja) 2023-11-28
AU2018375151B2 (en) 2025-06-26
JP2021503923A (ja) 2021-02-15
EP3716988A1 (en) 2020-10-07
JP2023159370A (ja) 2023-10-31
AU2018375151A1 (en) 2020-06-11
US20210393700A1 (en) 2021-12-23
US12233094B2 (en) 2025-02-25
WO2019108756A1 (en) 2019-06-06
CN111601606A (zh) 2020-08-28

Similar Documents

Publication Publication Date Title
US20250144151A1 (en) Interaction of fibroblasts and immune cells for activation and uses thereof
US12465621B2 (en) Mesenchymal stromal cells and uses related thereto
Slaney et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting
TWI698242B (zh) 利用血管母細胞產生間葉基質細胞之方法
DK1926813T3 (en) Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
AU782064B2 (en) Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation
ES2769778T3 (es) Composiciones inmunomoduladoras
US20230226119A1 (en) Umbilical cord derived regenerative and immune modulatory stem cell populations
JP2009536163A (ja) 免疫学的寛容および調節性前駆細胞
US20230014637A1 (en) Therapeutic Monocytic Lineage Cells
Chhabra et al. Current status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation
US20250375520A1 (en) Production of immune cells
HK40031603A (en) Interaction of fibroblasts and immune cells for activation and uses thereof
US20230149523A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
US20180360882A1 (en) Perispinal Perfusion by Administration of T regulatory Cells Alone or in Combination with Angiogenic Cell Therapies
US20230057356A1 (en) Enhancement of umbilical cord mesenchymal stem cell therapeutic activity by stimulators of t regulatory cells and/or cells expressing cd73
AU2018253517B2 (en) Cell populations having immunoregulatory activity, method for isolation and uses
WO2026010870A1 (en) Fibroblast compositions for treating aphthous ulcers
WO2025125443A1 (en) Production of immune cells
Blood Non-hematopoietic Stem and Progenitor Cells
Atoui Marrow stromal cells as" universal donor cells" for myocardial regenerative therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231120

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250709

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708